BEVERLY HILLS, March 11, (THEWILL) – Denmark, Austria and four other European countries, have suspended the use of AstraZeneca vaccines over concerns relating to blood clotting.
Estonia, Latvia, Lithuania and Luxembourg also halted the usage of the vaccine.
On Thursday, Danish health authorities said they were suspending the use of AstraZeneca’s COVID-19 vaccine for two weeks after some patients developed blood clots since receiving the jab.
READ ALSO: Death of Vaccinated Nurse Forces Austria To Suspend AstraZeneca Vaccine
The move comes “following reports of serious cases of blood clots among people vaccinated with AstraZeneca’s COVID-19 vaccine,” the Danish health authorities said in a statement.
But it cautiously added that “it has not been determined, at the time being, that there is a link between the vaccine and the blood clots.”
Austria announced on Monday that it had suspended the use of a batch of AstraZeneca vaccines after a 49-year-old nurse died of “severe blood coagulation problems” days after receiving an anti-COVID shot.
Spain said Thursday that it has not registered any cases of blood clots related to AstraZeneca’s COVID-19 vaccine so far and will continue administering the shots.
Spanish Health Minister, Carolina Darias, said she had been informed of cases of blood clots among recently vaccinated people in Austria, but added that, “so far, no causal relation between the vaccine and the blood clot events has been established,” and the European Medicines Agency (EMA) was evaluating the situation.
On Wednesday, EMA, Europe’s medicines watchdog, said a preliminary probe showed that the batch of AstraZeneca vaccines used in Austria was likely not to blame for the nurse’s death.
As of March 9, 22 cases of blood clots had been reported among more than 3 million people vaccinated in the European Economic Area, the EMA said.
“It is important to point out that we have not terminated the use of the AstraZeneca vaccine, we are just pausing its use,” Danish Health Authority director Soren Brostrom said in the statement.
Denmark said one person had died after receiving the vaccine. The EMA has launched an investigation into that death.
“There is broad documentation proving that the vaccine is both safe and efficient. But both we and the Danish Medicines Agency must act on information about possible serious side effects, both in Denmark and in other European countries,” Brostrom said.
The suspension, which will be reviewed after two weeks, is expected to slow down Denmark’s vaccination campaign.